Assurex Health

Assurex Health will use the MassArray system with its GeneSight Psychotropic pharmacogenetic test.

The deal, which included $225 million in upfront payments and up to $185 million in milestones, gives Myriad entry into the neuroscience space.

Despite the historical adoption and reimbursement challenges for PGx testing firms, Myriad said it would try to achieve value-based pricing for Assurex's GeneSight test.

The deal will grant Myriad entry into the neuroscience space, and will allow it to use Assurex's existing sales force to market its own mental health tests. 

Investors included existing shareholders Sequoia Capital, Claremont Creek Ventures, Cincinnati Children’s Hospital Medical Center, and Mayo Clinic.

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.

The funds will go toward efforts to drive clinical adoption and further develop Assurex's GeneSight products.

 

AdvaMedDx, a division of the Advanced Medical Technology Association, announced the election of several new members to its board of directors.

People In The News

NEW YORK (GenomeWeb News) – AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.

AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.

Pages

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.